• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 25 filed by Rubius Therapeutics Inc.

    3/28/23 4:23:38 PM ET
    $RUBY
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $RUBY alert in real time by email
    25 1 tm2310781d1_25.htm FORM 25

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D. C. 20549

     

     

     

    FORM 25

     

     

     

    NOTIFICATION OF REMOVAL FROM LISTING

    AND/OR REGISTRATION UNDER SECTION 12(b)

    OF THE SECURITIES EXCHANGE ACT OF 1934.

    Commission File Number 001-38586

     

     

     

    RUBIUS THERAPEUTICS, INC.

    THE NASDAQ GLOBAL SELECT MARKET

    (Exact name of Issuer as specified in its charter, and name of Exchange

    where security is listed and/or registered)

     

     

     

    c/o Verdolino & Lowey, P.C.

    124 Washington Street, Suite 101

    Foxborough, Massachusetts 02421

    (508) 543-1720

    (Address, including zip code, and telephone number, including area code, of Issuer’s principal executive offices)

     

    Common Stock, par value $0.001 per share

    (Description of class of securities)

     

     

     

    Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:

     

      ¨ 17 CFR 240.12d2-2(a)(1) 

     

      ¨ 17 CFR 240.12d2-2(a)(2) 

     

      ¨ 17 CFR 240.12d2-2(a)(3) 

     

      ¨ 17 CFR 240.12d2-2(a)(4) 

     

    ¨ Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange.

     

    x Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with the rules of the Exchange and the requirements of 17 CFR 240.12d2-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, Rubius Therapeutics, Inc. certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.

     

    Date: March 28, 2023 By: /s/ Craig Jalbert  
      Name: Craig Jalbert
      Title: President

     

     

    Get the next $RUBY alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RUBY

    DatePrice TargetRatingAnalyst
    9/13/2022Buy → Neutral
    Guggenheim
    2/25/2022$14.00 → $5.00Market Perform
    SVB Leerink
    11/9/2021$20.00 → $14.00Market Perform
    SVB Leerink
    10/19/2021$25.00 → $22.00Equal-Weight
    Morgan Stanley
    More analyst ratings